Owned by Ampersand Capital Partners, Brammer Bio is engaged in the clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy.
The post Thermo Fisher Scientific to buy viral vector CDMO Brammer Bio for $1.7bn appeared first on Pharmaceutical Business review.
Original Article: Thermo Fisher Scientific to buy viral vector CDMO Brammer Bio for $1.7bn